GLPwatch
Papers (9189)
Page 38 of 154, ranked by citation count.
- Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
- Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.
- A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.
- GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes.
- Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.
- Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.
- Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
- The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
- Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice.
- Liraglutide: a review of its use in the management of obesity.
- Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation.
- Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting.
- Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.
- Pancreatic insulin and exocrine secretion are under the modulatory control of distinct subpopulations of vagal motoneurones in the rat.
- Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
- Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.
- Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.
- Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.
- Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
- Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.
- Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
- Oligoarginine-linked polymers as a new class of penetration enhancers.
- Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities.
- Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
- Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
- Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide.
- Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
- Parabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia.
- GLP-1 Receptor Activation Inhibits Palmitate-Induced Apoptosis via Ceramide in Human Cardiac Progenitor Cells.
- Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
- Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury.
- GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
- Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
- GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
- GLP-1 as a target for therapeutic intervention.
- Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis.
- GLP-1 agonists in type 1 diabetes.
- Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery.
- Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.
- Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
- Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
- Glucagon-Like Peptide-1 Regulates the Proopiomelanocortin Neurons of the Arcuate Nucleus both Directly and Indirectly via Presynaptic Action.
- A narrative review of approved and emerging anti-obesity medications.
- Development of a reliable automated screening system to identify small molecules and biologics that promote human β-cell regeneration.
- Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
- Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations.
- Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
- Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
- Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
- Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway.
- Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
- Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.
- Oral semaglutide for the treatment of type 2 diabetes.
- Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials.
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
- Estimands, Estimators, and Estimates.
- Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca<sup>2+</sup>-PPP3/calcineurin-TFEB axis.
- Weight loss efficiency and safety of tirzepatide: A Systematic review.
- A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.